Do analysts rate PMCB or LGVN?

Longeveron has a consensus price target of $80.00, suggesting a potential upside of 1,074.74%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PMCB or LGVN more profitable?

Nuvilex has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Nuvilex's return on equity of 0.25% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 0.25% 0.18% Longeveron -1,977.59% -223.19% -150.20%

Do analysts prefer ALLR or PMCB?

Allarity Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 621.83%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Allarity Therapeutics is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALLR or PMCB more profitable?

Nuvilex's return on equity of 0.25% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -152.77% -46.50% Nuvilex N/A 0.25% 0.18%

Do analysts rate PMCB or NXTC?

NextCure has a consensus price target of $19.00, indicating a potential upside of 142.97%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better earnings and valuation, PMCB or NXTC?

NextCure is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A -$19.42M -$3.00 N/A NextCure N/A N/A -$55.84M -$8.70 N/A

Is PMCB or NXTC more profitable?

Nuvilex's return on equity of 0.25% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 0.25% 0.18% NextCure N/A -154.62% -100.19%

Do analysts prefer PMCB or NEUP?

Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 457.03%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PMCB or NEUP more profitable?

Nuvilex's return on equity of 0.25% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 0.25% 0.18% Neuphoria Therapeutics N/A -76.93% -54.76%

Do analysts prefer ALVR or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ALVR or PMCB?

AlloVir is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Nuvilex N/A N/A -$19.42M -$3.00 N/A

Is ALVR or PMCB more profitable?

Nuvilex's return on equity of 0.25% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Nuvilex N/A 0.25% 0.18%

Nuvilex (PMCB) Competitors

$0.49 0.00 (-0.98%)

As of 09/4/2026 04:00 PM Eastern

Compare

PMCB vs. LGVN, ALLR, NXTC, NEUP, and ALVR

Should you buy Nuvilex stock or one of its competitors? Nuvilex's main competitors and comparable companies include Longeveron (LGVN), Allarity Therapeutics (ALLR), NextCure (NXTC), Neuphoria Therapeutics (NEUP), and AlloVir (ALVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvilex compare to Longeveron?

Nuvilex (NASDAQ:PMCB) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 11.0% of Nuvilex shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Longeveron has a consensus price target of $80.00, suggesting a potential upside of 1,074.74%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nuvilex has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Nuvilex's return on equity of 0.25% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	0.25%	0.18%
Longeveron	-1,977.59%	-223.19%	-150.20%

Nuvilex has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

In the previous week, Longeveron had 1 more articles in the media than Nuvilex. MarketBeat recorded 1 mentions for Longeveron and 0 mentions for Nuvilex. Nuvilex's average media sentiment score of 0.00 equaled Longeveron'saverage media sentiment score.

Company	Overall Sentiment
Nuvilex	Neutral
Longeveron	Neutral

Nuvilex has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A
Longeveron	$1.20M	18.10	-$22.70M	-$9.90	N/A

Summary

Nuvilex beats Longeveron on 9 of the 14 factors compared between the two stocks.

How does Nuvilex compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Nuvilex's return on equity of 0.25% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
Nuvilex	N/A	0.25%	0.18%

Allarity Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Allarity Therapeutics has higher revenue and earnings than Nuvilex. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	70.60	-$11.23M	-$0.78	N/A
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Nuvilex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Allarity Therapeutics currently has a consensus price target of $10.25, suggesting a potential upside of 621.83%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Allarity Therapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Allarity Therapeutics' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
Nuvilex	Neutral

Summary

Allarity Therapeutics and Nuvilex tied by winning 6 of the 12 factors compared between the two stocks.

How does Nuvilex compare to NextCure?

Nuvilex (NASDAQ:PMCB) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 11.0% of Nuvilex shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NextCure has a consensus price target of $19.00, indicating a potential upside of 142.97%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

NextCure is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

Nuvilex has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, NextCure has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Nuvilex's return on equity of 0.25% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	0.25%	0.18%
NextCure	N/A	-154.62%	-100.19%

In the previous week, NextCure had 1 more articles in the media than Nuvilex. MarketBeat recorded 1 mentions for NextCure and 0 mentions for Nuvilex. Nuvilex's average media sentiment score of 0.00 beat NextCure's score of -0.63 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Neutral
NextCure	Negative

Summary

NextCure beats Nuvilex on 7 of the 13 factors compared between the two stocks.

How does Nuvilex compare to Neuphoria Therapeutics?

Nuvilex (NASDAQ:PMCB) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Neuphoria Therapeutics has higher revenue and earnings than Nuvilex. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A
Neuphoria Therapeutics	$15.65M	1.30	-$370K	-$11.06	N/A

Nuvilex's return on equity of 0.25% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	0.25%	0.18%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 11.0% of Nuvilex shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 457.03%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Nuvilex's average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nuvilex	Neutral
Neuphoria Therapeutics	Neutral

Nuvilex has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Summary

Nuvilex and Neuphoria Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Nuvilex compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Nuvilex's return on equity of 0.25% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Nuvilex	N/A	0.25%	0.18%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AlloVir is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A

66.1% of AlloVir shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 11.0% of Nuvilex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
Nuvilex	Neutral

Summary

Nuvilex beats AlloVir on 7 of the 9 factors compared between the two stocks.

Get Nuvilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMCB vs. The Competition

Export

Metric	Nuvilex	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.22M	$4.01B	$7.25B	$12.92B
Dividend Yield	N/A	3.60%	2.53%	9.14%
P/E Ratio	-0.16	12.71	273.54	25.43
Price / Sales	N/A	1,369.59	630.11	96.68
Price / Cash	N/A	108.60	77.08	52.44
Price / Book	0.16	16.14	12.85	6.17
Net Income	-$19.42M	-$22.80M	$3.49B	$350.08M
7 Day Performance	-5.53%	0.31%	1.04%	-0.14%
1 Month Performance	-17.54%	8.25%	5.52%	1.02%
1 Year Performance	-49.22%	49.17%	24.39%	14.51%

Nuvilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMCB Nuvilex	0.8429 of 5 stars	$0.49 -1.0%	N/A	-47.9%	$5.22M	N/A	N/A	4	Analyst Downgrade
LGVN Longeveron	1.4956 of 5 stars	$6.80 -3.3%	$80.00 +1,076.5%	-9.0%	$22.42M	$1.20M	N/A	20
ALLR Allarity Therapeutics	1.9086 of 5 stars	$1.38 +3.0%	$10.25 +642.8%	-17.9%	$21.32M	$345K	N/A	10
NXTC NextCure	2.9355 of 5 stars	$6.03 +3.4%	$19.00 +215.1%	+58.3%	$21.06M	N/A	N/A	90	News Coverage
NEUP Neuphoria Therapeutics	2.8911 of 5 stars	$3.77 -2.3%	$21.00 +457.0%	-68.4%	$20.86M	-$13.27K	N/A	N/A	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMCB) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvilex (PMCB) Competitors